CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on September 8, 2022
BENITEC BIOPHARMA INC.
3940 Trust Way
Hayward, California 94545
September 8, 2022
VIA EDGAR
Alan Campbell
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-1004
| Re: | Benitec Biopharma Inc. |
| Registration Statement on Form S-1 (File No. 333-266417) |
Dear Mr. Campbell:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-266417), as amended, so that it may become effective at 4:15 p.m., Eastern Time on September 12, 2022, or as soon thereafter as practicable.
[Signature page follows]
| Very truly yours, | ||||
| BENITEC BIOPHARMA INC. | ||||
| By: | /s/ Dr. Jerel Banks |
|||
| Name: | Dr. Jerel Banks | |||
| Title: | Chief Executive Officer | |||
[Signature Page to Acceleration Request]